Newly Approved

Truqap to treat breast cancer

Drug Name: Truqap Active Ingredient: capivasertib Indication: An AKT inhibitor used in combination with fulvestrant for the treatment of advanced HR-positive breast cancer Approval Date: 11/16/2023 Company: AstraZeneca More:

Defencath as a Catheter Lock Solution

Drug Name: Defencath Active Ingredient: taurolidine, heparin Indication: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter (Catheter…